GlaxoSmithKline received approval from the FDA for Avandamet for use as initial treatment of type 2 diabetes, as an adjunct to diet and exercise. Avandamet was previously approved as a second-line therapy for use in patients who were uncontrolled on metformin monotherapy. With this recent approval, physicians can start their type 2 diabetes patients on Avandamet. The approval for Avandamet coincides with the company's announcement that its supply of the drug has been re-established.